Close
ACHEMA MIDDLE EAST 2026

The FDA Has Finalized Its Prescription Drug REMS Guidelines

The FDA's Final Guidance on REMS programmes for prescription medications, has just been published. The document is officially titled Format and Content of a...

Drug Inspection Pact Between Switzerland And United States

The US and Switzerland have agreed to a Mutual Recognition Agreement (MRA) on pharmaceutical Good Manufacturing Practices (GMP). The US Food and Drug Administration (FDA)...

Considerable Rise In Healthcare Deals Expected In 2023

Pharma companies with plenty of cash were on one side of a $200 billion patent cliff. On the other hand, there were a lot...

A New Advancement In Disease Fighting Through Technology

To grasp the intricate pathology of many diseases today, scientists and researchers have achieved amazing advances in basic science. The ability of the human...

Clinical Trials Regulation Implementation Progress Report

The Clinical Trial Information System went live on January 31, 2022, which began the one-year transition period for all clinical trial sponsors. Clinical trial...

5 Concerns About Future of Developing Biotechnology In 2023

Drugmakers' initial stock offerings, which had been a dependable tradition for years, mostly stopped in 2022. Fewer than two dozen biotech businesses priced initial...

5 FDA Rulings To Keep An Eye On In The 2023 First Quarter

The biotechnology sector had a decline in 2022 that went beyond just falling stock prices. Additionally, only 37 new drugs were approved by the...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...